Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

1(13%)

Results Posted

100%(2 trials)

Terminated

3(38%)

Phase Distribution

Ph phase_1

88%

Ph early_phase_1

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Early Phase 1First-in-human

1(12.5%)

Phase 1Safety & dosage

7(87.5%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Terminated(4)

Detailed Status

Terminated3

Completed2

Not yet recruiting1

Recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (12.5%)

Phase 17 (87.5%)

Trials by Status

terminated338%

not_yet_recruiting113%

recruiting113%

completed225%

withdrawn113%

Recent Activity

1 active trials

Showing 5 of 8

recruitingphase_1

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

NCT07052305

not_yet_recruitingphase_1

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

NCT07200089

completedphase_1

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT04332653

completedearly_phase_1

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

NCT04781309

terminatedphase_1

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07052305Phase 1

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Recruiting

NCT07200089Phase 1

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Not Yet Recruiting

NCT04332653Phase 1

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Completed

NCT04781309Early Phase 1

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Completed

NCT03901573Phase 1

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Terminated

NCT04594811Phase 1

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Terminated

NCT02659800Phase 1

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Terminated

NCT04498325Phase 1

Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)